AAAAAA

   
Results: 1-10 |
Results: 10

Authors: GODFREY KR TANSWELL P BATES RA CHAPPELL MJ MADDEN FN
Citation: Kr. Godfrey et al., NONLINEAR PHARMACOKINETICS OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN 3 ANIMAL SPECIES - A COMPARISON OF MATHEMATICAL-MODELS, Biopharmaceutics & drug disposition, 19(2), 1998, pp. 131-140

Authors: WANGCHOW F FOX NL BERIOLI S BLUHMKI E INGELHEIM B MODI N TANSWELL P STUMP D GIBSON CM VANDEWERF F
Citation: F. Wangchow et al., A SIMPLE, INCREMENTAL WEIGHT-ADJUSTED DOSING SCHEME FOR TNK-TPA, A BIOENGINEERED VARIANT OF THE NATURAL TPA MOLECULE, Circulation, 98(17), 1998, pp. 1462-1462

Authors: GULBA DC TANSWELL P DECHEND R SOSADA M WEIS A WAIGAND J UHLICH F HAUCK S JOST S RAFFLENBEUL W LICHTLEN PR DIETZ R
Citation: Dc. Gulba et al., 60-MINUTE ALTEPLASE PROTOCOL - A NEW ACCELERATED RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR REGIMEN FOR THROMBOLYSIS IN ACUTE MYOCARDIAL-INFARCTION, Journal of the American College of Cardiology, 30(7), 1997, pp. 1611-1617

Authors: NARJES H MULLER TH WEISENBERGER H TANSWELL P DEICHSEL G SU CAPF
Citation: H. Narjes et al., INHIBITION OF PLATELET-FUNCTION, PK-PD RELATIONSHIP AND TOLERABILITY OF DT-TX-30-SE, A NOVEL COMBINED TXA(2) PGH(2) RECEPTOR BLOCKER AND THROMBOXANE SYNTHETASE INHIBITOR, IN HEALTHY-VOLUNTEERS/, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 64-64

Authors: TANSWELL P HEINZEL G WEISENBERGER H ROTH W
Citation: P. Tanswell et al., PHARMACOKINETIC-PHARMACODYNAMIC AND METABOLITE MODELING WITH TOPFIT, International journal of clinical pharmacology and therapeutics, 33(10), 1995, pp. 550-554

Authors: NARJES H MULLER TH WEISENBERGER H TANSWELL P DEICHSEL G SU CAPF
Citation: H. Narjes et al., PHARMACODYNAMICS OF DTTX-30-SE, A TXA(2) PGH(2) RECEPTOR BLOCKER AND THROMBOXANE (TX) SYNTHETASE INHIBITOR, AFTER MULTIPLE ORAL DOSING IN MAN/, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 141-141

Authors: SEIFRIED E OETHINGER M TANSWELL P HOEGEEDENOBEL E NIEUWENHUIZEN W
Citation: E. Seifried et al., INFLUENCE OF ACUTE MYOCARDIAL-INFARCTION AND RT-PA THERAPY ON CIRCULATING FIBRINOGEN, Thrombosis and haemostasis, 69(4), 1993, pp. 321-327

Authors: TANSWELL P NIEUWENHUIZEN W SEIFRIED E
Citation: P. Tanswell et al., PHARMACOKINETICS OF DEGRADATION PRODUCTS OF FIBRIN AND FIBRINOGEN DURING ALTEPLASE THERAPY OF ACUTE MYOCARDIAL-INFARCTION, Fibrinolysis, 7(6), 1993, pp. 408-415

Authors: TANSWELL P KOUP J
Citation: P. Tanswell et J. Koup, TOPFIT - A PC-BASED PHARMACOKINETIC-PHARMACODYNAMIC DATA-ANALYSIS PROGRAM, International journal of clinical pharmacology, therapy and toxicology, 31(10), 1993, pp. 514-520

Authors: TANSWELL P TEBBE U NEUHAUS KL GLASLESCHWARZ L WOJCIK J SEIFRIED E
Citation: P. Tanswell et al., PHARMACOKINETICS AND FIBRIN SPECIFICITY OF ALTEPLASE DURING ACCELERATED INFUSIONS IN ACUTE MYOCARDIAL-INFARCTION, Journal of the American College of Cardiology, 19(5), 1992, pp. 1071-1075
Risultati: 1-10 |